Press Release

Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis (MG) remains on track for mid-2024 On track to initiate Phase 2 study of Descartes-08 in systemic lupus erythematosus (SLE) in 1H24 as well as Phase 2 basket studies in additional autoimmune indications in 2H24 Following […]

GAITHERSBURG, Md., March 06, 2024 – Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in March: A presentation at the 2024 Leerink Partners Global Biopharma Conference at 8:40 a.m. ET on Wednesday, March

GAITHERSBURG, MD, March 5, 2024 – Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to a new employee. On March 1, 2024, the Company issued to this employee an option to purchase 375,000 shares

New facility expected to support expanded cGMP manufacturing of clinical and commercial supply of Company’s pipeline of mRNA cell therapies for the treatment of autoimmune diseases GAITHERSBURG, MD, March 5, 2024 – Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced its plans to transition its

Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy in myasthenia gravis (MG) remains on track for mid-2024 Positive 12-month follow-up data from Phase 2a study in MG reported today; durable depletion of autoantibodies and clinically meaningful improvements in MG severity scores observed approximately 10 months after last

Durable depletion of autoantibodies and clinically meaningful improvements in myasthenia gravis (MG) severity scores observed after one-year follow-up period without need for lymphodepleting chemotherapy Descartes-08 observed to be well tolerated following administration in outpatient setting Publication is in peer review and available on the preprint server, medRxiv Topline data from Phase 2b placebo-controlled study continues

– Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian’s wholly owned pipeline includes a Phase 2 lead asset, Descartes-08, for which deep and durable responses have been observed in patients with myasthenia gravis (MG) – – Multiple near-term catalysts, including data from

Modifying patients’ T-cells with mRNA to express a chimeric antigen receptor (rCAR-T therapy), a novel approach to treat myasthenia gravis and other autoimmune diseases. Gaithersburg, MD—June 22, 2023 – Cartesian Therapeutics, a clinical-stage biotechnology company pioneering cell therapies for autoimmune diseases, announced today the publication of a landmark paper in The Lancet Neurology. The study describes

Gaithersburg, MD—April 25, 2023 – Cartesian Therapeutics, a fully integrated biopharmaceutical company pioneering RNA cell therapy for autoimmune diseases and cancer, today announced the appointment of three world-renowned scientists and engineers as charter members of the company’s Scientific Advisory Board (SAB): Prof. Jennifer Elisseeff (Johns Hopkins University), Prof. Andrés García (Georgia Institute of Technology), and Prof. David

Gaithersburg, MD—March 28, 2023 – Cartesian Therapeutics, a fully integrated biopharmaceutical company pioneering RNA cell therapy for autoimmune diseases and cancer, today announced the appointment of five internationally recognized experts in autoimmune diseases.  Cartesian’s appointments include distinguished physicians and scientists as leaders in clinical trials and medicine. “Cartesian is proud to have these prestigious, multidisciplinary advisors